Flamicort 40

Where oral therapy is not feasible or is temporarily undesirable in the judgement of the physician, Flamicort injection 40 mg/ml is indicated for intramuscular use as follows:

• Allergic diseases
• Rheumatic disorders, as adjunctive therapy for short-term administration (to tide the patient over an acute episode exacerbation) in: post-traumatic osteoarthritis, synovitis of osteoarthritis, rheumatoid arthritis, acute or sub-acute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute gouty arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile rheumatoid arthritis.
• Collagen diseases, during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus, acute rheumatic carditis.
• Dermatological diseases, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe psoriasis.
• Edematous state, to induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.